EMMA
EMMAUS LIFE SCIENCES INC
stockOTC
emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.07 | 2026-09-28 | -35.53% | -61.250 |
| 1M | 0.06 | 2026-09-04 | -29.84% | 1.126 |
| 3M | 0.01 | 2026-07-06 | +269.50% | 1.984 |
| 6M | 0.01 | 2026-04-07 | +317.82% | 2.468 |
| 1Y | 0.01 | 2025-10-06 | +263.79% | -0.602 |
| 2Y | 0.04 | 2024-10-03 | +5.76% | — |
| 5Y | 1.41 | 2021-10-05 | -97.01% | -2.457 |
EMMAUS LIFE SCIENCES INC (OTC:EMMA) stock price today is $0.04, and today's volume is 20,250. EMMA is down 35.077% today. The 30 day average volume is 236,618. EMMA market cap is $2.70M with 63.87M shares outstanding.